Clinical Toolkit

  • Risk factors. Several factors can increase your risk of psoriatic arthritis, including:


Psoriatic arthritis (PsA) is a complex and heterogeneous disease that leads to joint damage and deformities that significantly impact patients’ quality of life. Delays in diagnosis are common in PsA and are associated with disease progression and poorer physical functioning. Early initiation of therapy and the development of new treatments that target the underlying pathophysiology of the disease have the potential to shift goals of treatment for PsA from pain and stiffness reduction to disease remission.

However, the ongoing COVID-19 pandemic has complicated the management of patients with PsA. Although current evidence suggests that patients with PsA are not at increased risk of developing severe COVID-19, they are more likely to have comorbidities that increase the risk for COVID-19-related complications. Additionally, it is unknown if treatments for PsA impact the course of COVID-19.

Click on the links below to explore resources on the diagnosis and management of PsA during the COVID-19 pandemic.

Scroll to Top

Updates in the Treatment and Prevention of COVID-19

An investigational, oral COVID-19 antiviral candidate reduced the risk of hospitalization or death by 89% in an interim analysis

An investigational oral antiviral candidate consisting of PF-07321332 plus ritonavir (Paxlovid™) significantly reduced hospitalization and death in non-hospitalized adult patients with COVID-19 at high risk of progressing to severe illness. An interim analysis of the phase 2/3 EPIC-HR trial showed an 89% reduction in the risk of COVID-19-associated hospitalization or death from any cause at day 28 in the antiviral group compared with the placebo group in patients treated within three days of symptom onset (0.8% vs 7.0%, respectively; P <.0001). Similar results were observed in patients treated within five days of symptom onset (1.0% vs 6.7%; P <.0001). No deaths were reported in patients who received  the antiviral treatment compared with 10 deaths (1.6%) in patients who received placebo. Treatment-emergent adverse events were comparable between antiviral treatment (19%) and placebo (21%) groups and were mostly mild in intensity. Fewer serious adverse events (1.7% vs 6.6%) and discontinuation of the study drug due to adverse events (2.1% vs 4.1%) were observed in patients receiving the antiviral treatment compared with placebo, respectively.


Mahase E. Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021;375:n2713. Available at